EdoxabaN or Warfarin Therapy In Device Procedures in Patients With Non-Valvular Atrial Fibrillation
Status:
Terminated
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective randomized comparative evaluation of Edoxaban and Warfarin for safety
and efficacy in perioperative use in patients with non-valvular atrial fibrillation (AF)
undergoing clinically indicated implantation or replacement of cardiovascular implantable
electrical devices.The primary objective is to compare the rates of local and systemic
bleeding in subjects randomized to Edoxaban compared to subjects randomized to continuous
warfarin in within 30 days of cardiac rhythm device implant with concomitant non-valvular AF.